This website uses cookies to enhance customer’s convenience to use the site and keep its functions working properly. For more information about using cookies, please refer to "Terms of Use."
Always putting healthier
lives first
News
-
Sawai Group Reports FY2024 Financial Results
-
Sawai Group Reports Third Quarter FY2024 Financial Results
-
Integrated Report 2024 has been releasedOpens in a new window.
-
Sawai Group Reports Financial Results for the first half of FY2024
-
Sawai Group Reports Financial Results for the first three months of FY2024
-
Sawai Receives Approvals for a Single Generic Drug with One StrengthOpens in a new window.
-
Sawai Announces Listing of Five Generic Drugs with 10 StrengthsOpens in a new window.
-
Sawai Receives Approvals for Six Generic Drugs with 11 StrengthsOpens in a new window.
-
Sawai Announces Listing of Two Generic Drugs with Three StrengthsOpens in a new window.
-
Sawai Receives Approvals for Three Generic Drugs with Four StrengthsOpens in a new window.
(Corrections Corrections of Numerical Data)Revision of Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 （PDF：763KB）
Notice Regarding Recording of Other Expenses (Provision for Loss on Litigation) （PDF：385KB）
(Revised Version) FY2024 Financial Results Presentation （PDF：5354KB）
Notice Concerning Revision of FY2024 Financial Results Presentation Material （PDF：4953KB）
Notice of the 4th Annual General Meeting of Shareholders
Company Information
